Novavax Inc said on Wednesday it has entered a supply and license agreement with the Serum Institute of India for the development and commercialization of its COVID-19 vaccine candidate.
The Indian drugmaker will have exclusive rights for the vaccine in India during the term of the deal and non-exclusive rights during the "Pandemic Period" in all countries other than those designated by the World Bank as upper-middle or high-income countries.
The deal was signed on July 30
On Tuesday, Novavax reported that its experimental COVID-19 vaccine produced high levels of antibodies against the novel coronavirus in a small, early-stage clinical trial, and that it could start a large pivotal Phase III trial as soon as late September.
![Sky is the limit: IndiGo is now tenth largest airline by capacity globally; growth indisputable [details]](https://data1.ibtimes.co.in/en/full/767455/sky-limit-indigo-now-tenth-largest-airline-by-capacity-globally-growth-indisputable-details.jpg?w=220&h=138)
![Sky is the limit: IndiGo is now tenth largest airline by capacity globally; growth indisputable [details]](https://data1.ibtimes.co.in/en/full/767455/sky-limit-indigo-now-tenth-largest-airline-by-capacity-globally-growth-indisputable-details.jpg?w=220&h=135)